Synageva BioPharma Announces Pricing of Public Offering of Common Stock

  Synageva BioPharma Announces Pricing of Public Offering of Common Stock

Business Wire

LEXINGTON, Mass. -- January 3, 2013

Synageva BioPharma Corp.  (“Synageva”) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare disorders,
today announced the pricing of its previously announced underwritten public
offering of common stock consisting of 2,150,000 shares at $47.53 per share.
In connection with this offering, Synageva granted to the underwriters a
30-day option to purchase  322,500 additional shares of common stock.

Morgan Stanley and J.P. Morgan are acting as joint book-running managers in
the offering, and Cowen and Company, Canaccord Genuity Inc., and Leerink Swann
LLC are acting as co-managers in the offering.

The securities described above are being offered by Synageva pursuant to a
Form S-3 shelf registration statement (including a base prospectus) previously
filed the Securities and Exchange Commission (“SEC”). Before you invest, you
should read the prospectus in the registration statement and related
prospectus supplement that Synageva has filed with the SEC for more complete
information about Synageva and this offering. The prospectus supplement is
available for free by visiting EDGAR on the SEC’s website located at Copies of the prospectus supplement and accompanying prospectus
may also be obtained from the offices of Morgan Stanley & Co. LLC, 180 Varick
Street, 2nd Floor, New York, New York 10014, Attn: Prospectus Department, by
calling toll-free (866) 718 1649 or by email at,
or from the offices of J.P. Morgan Securities LLC via Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free
(866) 803-9204.

This news release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other

About Synageva BioPharma Corp.

Synageva is a clinical stage biopharmaceutical company focused on the
discovery, development, and commercialization of therapeutic products for
patients with life-threatening rare diseases and unmet medical need. Synageva
has several protein therapeutics in its pipeline. The company has assembled a
team with a proven record of bringing orphan therapies to patients.

Forward-Looking Statements

This news release and oral statements made from time to time by Synageva
representatives in respect of the same subject matter may contain
“forward-looking statements” under the provisions of the Private Securities
Litigation Reform Act of 1995. Such statements can be identified by
introductory words such as “expects,” “plans,” “intends,” “believes,” “will,”
“estimates,” “forecasts,” “projects,” or words of similar meaning, and by the
fact that they do not relate strictly to historical or current facts. Many
factors may cause actual results to differ materially from forward-looking
statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known, including those identified under the
heading “Risk Factors” in the Company’s prospectus supplement filed with the
Securities and Exchange Commission (the “SEC”) on January 3, 2013 and other
filings the Company periodically makes with the SEC, and others of which are
not. No forward-looking statement is a guarantee of future results or events,
and one should avoid placing undue reliance on such statements. Synageva
undertakes no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or otherwise.

“Dedicated to Rare Diseases®” is a registered trademark and “Synageva
BioPharma™” is a trademark of Synageva BioPharma Corp.


Matthew Osborne, 781-357-9947
Press spacebar to pause and continue. Press esc to stop.